However, in a sensitivity analysis of the REWIND study with dulaglutide, the relative risk reduction for a 40% or 50% decrease in eGFR was 30% and 44%, both significant, in the dulaglutide group compared to placebo, respectively.92 This lower risk of developing macroalbuminuria was also confirmed in an exploratory analysis of the ELIXA (lixisenatide) study.93 In the EXSCEL study (exenatide LAR), renal episodes were analyzed as additional microvascular episodes, and no differences were observed in the risk of episodes related to decreased eGFR, but differences were observed in the composite episode, which included decreased eGFR and macroalbuminuria, although only after adjustment94 (Table 2)
Is Health RX GLP-1 suitable during pregnancy
Mosenzon O, Blicher TM, Rosenlund S, et al
Nutrient-dense foods that raise glutathione levels
The body clears crystallised fat cells through its own lymphatic pathways, ensuring a natural structural adjustment
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials